Virtual Library
Start Your Search
B. Jacobson
Author of
-
+
P1.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 233)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P1.04-110 - Use of Blood Outgrowth Endothelial Cells as a Carrier of Oncolytic Vesicular Stomatitis Virus-Interferon Beta in Treating Metastatic NSCLC (ID 1008)
09:30 - 17:00 | Author(s): B. Jacobson
- Abstract
Background:
Oncolytic viruses have been extensively studies in the past two decades and are promising for cancer treatment. We have shown previously that vesicular stomatitis virus expressing interferon β (VSV-IFNβ) has oncolytic activity in vitro and in vivo in an immune competent mouse model of NSCLC. However, for treatment of metastatic NSCLC, intravenous delivery of VSV-IFNβ still faces several challenges, such as rapid clearance from bloodstream due to serum complement as well as sequestration in lymphoid tissue. In order to overcome these problems, we are exploring the potential role of blood outgrowth endothelial cells (BOECs) as carrier cells to deliver VSV-IFNβ to lung tumor sites.
Methods:
Efficacy of VSV-IFNβ-infected BOECs in transferring VSV-IFNβ to co-cultured human lung cancer cell lines in presence or absence of VSV antiserum were tested in vitro. A/J mice intravenously injected with LM2 non-small cell lung cancer cells were treated with PBS, VSV-IFNβ or VSV-IFNβ-infected BOECs (3 sequential treatments 3 weeks after tumor cell injection). Tumor growth, intratumor viral titer and survival were tested.
Results:
We demonstrated that VSV-IFNβ-infected BOECs can effectively transfer VSV-IFNβ to co-cultured human lung cancer cells and result in viral oncolysis even in the presence of VSV antiserum. In mice bearing metastatic lung cancer, BOECs injected via tail vein preferentially accumulated in lung tumor tissues, and were absent in either normal lung or liver tissues. Moreover, treatment with VSV-IFNβ-BOECs had higher and more sustained intra-tumoral viral titers comparing with those treated with either PBS or naked VSV-IFNβ. Furthermore, there was a trend (p=0.09) towards reduced tumor burden in the VSV-IFNβ-BOEC treated mice (n=5). Currently, we are testing the survival benefit of VSV virus in metastatic lung cancer model.
Conclusion:
In summary, the pre-clinical data showed promise to support developing a clinical protocol in the near future to assess the safety, response and efficacy of VSV-IFNβ-infected BOECs in treatment of metastatic lung cancer.
-
+
P2.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 234)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.04-052 - Targeting Oncogenic Eukaryotic Protein Translation in Thoracic Malignancies with Small-Molecule Inhibitors (ID 3094)
09:30 - 17:00 | Author(s): B. Jacobson
- Abstract
Background:
Hyperactivation of cap-mediated translation can induce oncogenic transformation by enhancing the translation of a subset of mRNAs involved in the genesis, maintenance and progression of cancer.In this investigation, disabling the eIF4F complex by disrupting the eIF4E-mRNA-cap interaction is evaluated as a therapy for mesothelioma and non-small cell lung cancer (NSCLC).
Methods:
Cell lines and culture. H513 and H2373 were from American Type Culture Collection (ATCC) and cultured in either RPMI 1640 containing 10% calf serum supplemented with 10% calf serum and maintained at 37[o]C. Cell proliferation assay. 5000 cells were seeded into wells of 96 well plates. Following overnight incubation cells were treated with varying doses of cpd 267, 272 or pemetrexed for 72 h. Viable cells were counted employing Cell Counting Kit 8 (Dojindo). Cap-affinity assay. Cell lysate was mixed with 50 mL of a 50% mixture of m[7]GTP-Sepharose resin with and without 400 mM of cpd 267 for 2 h at 4[o]C to capture eIF4E and eIF4G. The captured bound proteins were eluted and prepared for immunoblot analysis. Immunoblot analysis. Protein samples were separated by SDS-PAGE and transferred to Hybond PVDF membrane. Blots were probed for eIF4E and eIF4G (both from Cell Signaling and diluted 1:1000). Detection was carried out using ECL Plus Western Blotting System (Amersham) to visualize the bands of interest.
Results:
Mesothelioma and NSCLC cells were treated with small-molecule inhibitors [compounds 267 and 272] that mimic the cap structure that displace capped mRNAs from the eIF4F complex resulting in suppression of cap-dependent translation of malignancy-related proteins. Treatment with the compounds resulted in a dose dependent decrease in cell viability. Combination therapy of the compounds with cytotoxic agents further decreased cell survival. Binding to a synthetic cap-analogue was employed to assess the strength of eIF4F complex activation in lysates exposed to the compounds.
Conclusion:
These novel compounds reduce cancer cell proliferation,reduce eIF4F complex formation and sensitizes mesothelioma and NSCLC cells to cytotoxic agents.
